CLINICAL TRIALS PROFILE FOR DAYTRANA
✉ Email this page to a colleague
All Clinical Trials for Daytrana
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00434213 ↗ | Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA | Completed | Noven Therapeutics | Phase 4 | 2007-01-01 | This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks. |
| NCT00499863 ↗ | Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD | Completed | Noven Therapeutics | Phase 3 | 2007-07-01 | To assess the efficacy and safety of efficacy of MTS compared to placebo |
| NCT00501293 ↗ | Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD | Completed | Noven Therapeutics | Phase 3 | 2007-08-01 | To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD |
| NCT00506285 ↗ | Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD | Completed | Shire | Phase 3 | 2007-06-01 | This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects. |
| NCT00506285 ↗ | Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD | Completed | University of Utah | Phase 3 | 2007-06-01 | This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Daytrana
Condition Name
Clinical Trial Locations for Daytrana
Trials by Country
Clinical Trial Progress for Daytrana
Clinical Trial Phase
Clinical Trial Sponsors for Daytrana
Sponsor Name
